Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.2053
Abstract: 2053 Background: Interleukin-12 (IL-12), a master regulator of the immune system, results in anti-tumor responses in preclinical models, but safe use requires tightly controlled production. It was conditionally produced in Ph1 “main” study (NCT02026271) in… read more here.
Keywords: controlled monotherapy; subjects recurrent; main study; evaluation controlled ... See more keywords